文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

Aficamten 在症状轻微梗阻性肥厚型心肌病患者中的疗效:SEQUOIA-HCM 试验结果

Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial.
PubMed 文献 · Eur Heart J · 2025-05-17

SEQUOIA-HCM 试验(N=282)按基线症状严重程度分组,比较 aficamten 对梗阻性肥厚型心肌病(oHCM)患者的疗效。症状轻微组(n=118)定义为 NYHA II 级且 KCCQ-CSS≥80,中重度症状组(n=150)为 NYHA II/III/IV 级且 KCCQ-CSS<80。结果显示,aficamten 治疗 24 周时,两组峰值耗氧量(pVO2)变化无差异(中重度组 1.8 mL/kg/min,n=71;轻微组 1.6 mL/kg/min,n=62;结论认为症状轻微患者也可考虑 aficamten 治疗。

要点

  • 两组 NYHA 分级、流出道压差及 NT-proBNP 变化无显著差异。

核心结论

  • 症状轻微的 oHCM 患者接受 aficamten 治疗可在多项临床相关结局上获得显著改善,且与症状更重的患者总体相似。
  • 症状较轻的患者也可考虑使用 aficamten 治疗。

研究设计与样本

  • SEQUOIA-HCM 试验(NCT05186818)的事后分析,共纳入 282 例 oHCM 患者。
  • 按基线症状严重程度分组:症状轻微组(n=118)定义为 NYHA II 级且 KCCQ-CSS≥80;中重度症状组(n=150)定义为 NYHA II/III/IV 级且 KCCQ-CSS<80。
  • 主要终点为基线至第 24 周峰值耗氧量(pVO2)的变化;次要终点包括 NYHA 分级、KCCQ-CSS、流出道压差和 NT-proBNP 的变化。

主要发现

  • 次要终点(NYHA 分级、静息或 Valsalva 压差、NT-proBNP)变化在两组间无显著差异。
  • 治疗中出现严重不良事件在两组均不常见。

关键数值与推荐

  • 症状轻微定义:NYHA II 级且 KCCQ-CSS≥80。
  • 中重度症状定义:NYHA II/III/IV 级且 KCCQ-CSS<80。

临床怎么用

  • 对于 NYHA II 级且 KCCQ-CSS≥80 的 oHCM 患者,aficamten 可带来与症状更重患者相似的 pVO2 及多项次要终点获益。
  • 症状轻微患者使用 aficamten 后 KCCQ-CSS 亦显著改善,但改善幅度可能小于中重度症状患者。
  • 治疗中出现严重不良事件不常见,支持在症状轻微患者中考虑 aficamten 治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with obstructive hypertrophic cardiomyopathy (oHCM) treated with aficamten in SEQUOIA-HCM (NCT05186818) demonstrated marked improvement in symptoms and functional capacity. This analysis explores whether oHCM and mild symptoms patients experience similar clinical benefits with aficamten as patients with more advanced limitations. METHODS: Patients in SEQUOIA-HCM (N = 282) were grouped at baseline according to symptom severity. Mild symptoms (n = 118) were defined as New York Heart Association (NYHA) class II and Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) ≥ 80, and moderate to severe symptoms (n = 150) as NYHA class II/III/IV and KCCQ-CSS <80. Primary endpoint was change in peak oxygen uptake (pVO2) from baseline to Week 24; secondary endpoints included change in NYHA class, KCCQ-CSS, outflow tract gradients, and N-terminal pro-B-type natriuretic peptide (NT-proBNP). RESULTS: In aficamten-treated patients, change at Week 24 was not different between moderate to severe (1.8 mL/kg/min; n = 71) and mild (1.6 mL/kg/min; n = 62) symptom groups (P = .8). Likewise, the change in secondary endpoints (NYHA class, resting or Valsalva gradients, and NT-proBNP) did not differ significantly between the two symptom groups. Both groups experienced statistically significant improvements in KCCQ-CSS, but the extent of improvement was greater in the advanced symptom group (P = .02 for interaction). Treatment-emergent serious adverse events were infrequent in both groups. CONCLUSIONS: Patients with oHCM and mild symptoms treated with aficamten achieved significant improvement across a range of clinically relevant outcomes and generally similar to patients with more advanced symptoms. Less severely symptomatic patients could be considered for aficamten treatment.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Maron MS, Gimeno JR, Veselka J, et al. Efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy and mild symptoms: results from the SEQUOIA-HCM trial. Eur Heart J. 2025. PMID: 41120118. doi:10.1093/eurheartj/ehaf364

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。